While a previous study also showed the effectiveness of the WEE1 inhibitor adavosertib as a monotherapy in KRAS-mutant cancer cell lines with TP53 mutations,34 our research extends this understanding by demonstrating enhanced therapeutic benefits when combining KRAS inhibitors with WEE1 inhibitors in both sotorasib-sensitive and -resistant KRAS-G12C with TP53 mutations. This evidence concerns the gene TP53 and cancer.